Immortal time bias, absent comparator, and CA19-9 overinterpretation in cholangiocarcinoma immunotherapy
Digestive and Liver Disease · 2026-10
DOI: 10.1016/j.dld.2026.10.017 ↗Kurz gefasst
Leserbrief in der Zeitschrift Digestive and Liver Disease, 2026-10. Verfasst von Haleema Rahman. Beteiligte Einrichtung: Rawal Institute of Health Sciences, Islamabad, Pakistan. Electronic address: halymarahman124@gmail.com. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We read with interest the study by Li et al. [1], which reports progression patterns and outcomes among 131 patients with unresectable, recurrent, or metastatic cholangiocarcinoma treated with immune checkpoint inhibitors (ICIs). The two-centre cohort provides useful descriptive information in an area where post-immunotherapy failure patterns remain incompletely characterized. The authors acknowledge retrospective selection bias, limited sample size, absent molecular profiling, and variability in the definition of oligo-progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rawal Institute of Health Sciences, Islamabad, Pakistan. Electronic address: halymarahman124@gmail.com.
Zitieren
APA
Rahman, H. (2026). Immortal time bias, absent comparator, and CA19-9 overinterpretation in cholangiocarcinoma immunotherapy. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2026.10.017
Vancouver
Rahman H. Immortal time bias, absent comparator, and CA19-9 overinterpretation in cholangiocarcinoma immunotherapy. Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2026.10.017
BibTeX
@article{Rahman2026,
author = {Rahman, Haleema},
title = {Immortal time bias, absent comparator, and CA19-9 overinterpretation in cholangiocarcinoma immunotherapy},
journal = {Digestive and Liver Disease},
year = {2026},
doi = {10.1016/j.dld.2026.10.017}
}
EUVIMED